IGM Biosciences Logo
  • Home
  • About Us
  • Technology
  • Pipeline
    • IGM-2323: CD20 x CD3
    • IGM-8444: DR5
    • IGM-7354: IL-15 x PD-L1
    • Research & Discovery Programs
  • Team
    • Management
      • Fred M. Schwarzer, CEO
      • Bruce Keyt, CSO
      • Daniel S. Chen, CMO
      • Misbah Tahir, CFO
      • Stephen F. Carroll, VP
      • Wayne Godfrey, VP
      • Elizabeth Haanes, VP
      • Eric Humke, VP
      • Marvin S. Peterson, VP
      • Angus M. Sinclair, VP
      • Suzette Tauber, VP
    • Board of Directors
    • Scientific Advisory Board
  • News & Publications
  • Investors
  • Join Us
  • Contact Us
  • MENU

News

igm-news-hero-03

News & Publications

IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma

April, 2014
Read More...
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Home
  • About Us
  • Technology
  • Pipeline
    • IGM-2323: CD20 x CD3
    • IGM-8444: DR5
    • IGM-7354: IL-15 x PD-L1
    • Research & Discovery Programs
  • Team
    • Management
      • Fred M. Schwarzer, CEO
      • Bruce Keyt, CSO
      • Daniel S. Chen, CMO
      • Misbah Tahir, CFO
      • Stephen F. Carroll, VP
      • Wayne Godfrey, VP
      • Elizabeth Haanes, VP
      • Eric Humke, VP
      • Marvin S. Peterson, VP
      • Angus M. Sinclair, VP
      • Suzette Tauber, VP
    • Board of Directors
    • Scientific Advisory Board
  • News & Publications
  • Investors
  • Join Us
  • Contact Us

IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View, CA 94043
(650) 965-7873
info@igmbio.com

All content © IGM Biosciences, Inc.

A SiteOrigin Theme